<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="856">
  <stage>Registered</stage>
  <submitdate>26/10/2005</submitdate>
  <approvaldate>2/11/2005</approvaldate>
  <actrnumber>ACTRN12605000707662</actrnumber>
  <trial_identification>
    <studytitle>A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled,
Multicenter Study Of Ularitide In The Treatment Of Subjects With
Acute Decompensated Heart Failure</studytitle>
    <scientifictitle>A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled,
Multicenter Study Of Ularitide In The Treatment Of Subjects With
Acute Decompensated Heart Failure</scientifictitle>
    <utrn />
    <trialacronym>Ularitide-1501</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Decompensated Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a randomized, 2-arm study in which ularitide (15 ng/kg/min) or placebo will
be administered IV continuously over 24 hours, in addition to standard therapy. Subjects must receive the dose of study drug within one hour after
randomization.</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the safety of ularitide
(15 ng/kg/min IV over 24 hours) to placebo in subjects with
symptomatic acute decompensated heart failure.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To compare the efficacy of ularitide
(15 ng/kg/min IV over 24 hours) to placebo in subjects with
symptomatic acute decompensated heart failure.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the pharmacokinetics, pharmacodynamics,
and immunogenicity of IV ularitide in subjects with symptomatic
ADHF.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults who require hospitalization in a monitored bed for ADHF. Symptomatic ADHF (see Section 4.2 for definingcharacteristics). A negative urine pregnancy test result in women ofchildbearing potential within 24 hours of dosing. Ability of subject or authorized guardian to provide informedconsent (all sites) and permission to use protected health information (US sites only). </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Systolic blood pressure (BP) 110 or &gt;200 mmHg at screening and within 10 minutes of study drug administration. Ongoing acute coronary syndrome, acute myocarditis orconstrictive pericarditis, obstructive hypertrophiccardiomyopathy, hemodynamically significant arrhythmias, stenotic valvular disease, or congenital heart disease; acutemyocardial infarction within 30 days of randomization. Use of restricted medications or procedures (see details in Section 4.3). Cardiogenic shock, volume depletion, severe electrolyteimbalance, renal disorder with serum creatinine &gt;2.5 mg/dL (220 micromol/L) or planned ultrafiltration or dialysis or anyother clinical condition that would contraindicate the use of an IV vasodilator. Coronary artery bypass grafting within 90 days. Suspicion of pulmonary embolism. Cerebrovascular accident (CVA) within 180 days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation of study drug will be done Iteractive Voice Register System</concealment>
    <sequence>Random allocation sequence is done by computer generated system. When a patient is confirmed as eligible for the study, the Investigator will phone the IVRS system and the next treatment number available will be allocated for this patient's randomization number. The pharmacist will then prepare the study drug using the allocated subject number.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protein Design Labs, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protein Design Labs Inc</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Icon Clinical Research Organisation will represent the sponsor in Australia</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Nepean Hospital Derby Street
Penrith NSW 2751 ethics submission due on 12th Oct 05.

Royal Adelaide Hospital Level 6, 
Outpatients Building North Terrace, 
SA 5000 ethics submission 19th Oct 05</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Richard Shames</name>
      <address>34801 Campus Drive
Fremont CA 94555</address>
      <phone>+1 5105791176</phone>
      <fax />
      <email>rshames@pdl.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lenilyn Manlapaz-Espiritu</name>
      <address>34801 Campus Drive
Fremont CA 94555</address>
      <phone>+1 5105791176</phone>
      <fax />
      <email>lespiritu@pdl.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>